objective response rate
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
objective response rate
Oct 4, 2024, 09:43 |
Insight
Deridre Kelly: Ph2 Capmatinib in METex14 NSCLC
Deridre Kelly, Professor of Paediatric Hepatology at the University of Birmingham, sharen on X: "New…
Jun 30, 2024, 04:58 |
Blog
Victor Moreno: Botensilimab and balstilimab in treating heavily pre-treated patients with MSS mCRC
Victor Moreno, Director of Clinical Research at START Madrid-FJD, shared a post on LinkedIn: .…
May 24, 2024, 13:24 |
Insight
Erman Akkus Summarizes 5-year Results of CheckMate 040
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: “Nivolumab plus ipilimumab…
May 18, 2024, 01:12 |
Opinion
Results from the IMpassion132 trial presented at ESMO Breast 24
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “Results from the IMpassion132 trial presented…
May 14, 2024, 10:05 |
Blog
Amalya Sargsyan: Novel weapons in LCSM to be presented at ASCO
Amalya Sargsyan, Medical Oncologist at the Yeolyan Oncology and Hematology Center, shared a post on X:…
May 9, 2024, 00:21 |
Blog
Enes Erul: Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors
Enes Erul, Oncology Fellow at Ankara Üniversitesi, shared on X: “Trastuzumab deruxtecan shows promise in HER2-mutant…
All:
6
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube